CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test Two-Pronged attack on tough blood cancers
Disease control CompletedThis early-stage study tested a combination of two drugs, veliparib and temozolomide, in adults with acute leukemias that had returned or were hard to treat. The main goal was to find the highest dose patients could safely tolerate. Researchers also wanted to see if the drug comb…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope to keep leukemia at bay after risky transplant
Disease control CompletedThis study tested the safety and best dose of a drug called enasidenib, given as a maintenance therapy to prevent cancer from returning. It involved 23 adults with specific genetic types of leukemia or related blood cancers who had just received a stem cell transplant. The main g…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug combo aims to fight back when leukemia returns after transplant
Disease control CompletedThis study tested a two-part treatment for people whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) came back after a donor stem cell transplant. It combined a drug called guadecitabine, which may slow cancer growth, with infusions of the donor's white blood ce…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Early trial tests Four-Drug combo to train immune system against blood cancers
Disease control CompletedThis early-stage study tested a combination of a cancer vaccine, chemotherapy, and immunotherapy in 8 patients with certain high-risk blood cancers. The main goal was to check the safety of this four-drug approach and see if it could help the body's immune system better target an…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
First patient receives experimental cell therapy for Tough-to-Treat leukemia
Disease control CompletedThis was a very early, exploratory study to check the safety of a new type of cell therapy called LILRB4 STAR-T cells in adults with a specific form of leukemia that has not responded to other treatments. Only one patient was enrolled to receive the treatment after a short course…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Gentler transplant strategy tested for tough blood cancers
Disease control CompletedThis study tested a two-step, lower-intensity stem cell transplant for patients with high-risk blood cancers like leukemia and lymphoma. The goal was to use milder chemotherapy and radiation before the transplant to reduce side effects while still allowing the donor's immune cell…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC
-
First human test of new leukemia pill seeks safe dose
Disease control CompletedThis was the first study in people to test the safety of a new oral drug called JNJ-74856665 for advanced blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The main goal was to find the highest dose patients could tolerate without severe side ef…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Feb 27, 2026 15:06 UTC